TY - JOUR
T1 - Clinical, Gender, Socioeconomic Characteristics and Outcomes of Individuals Receiving Hepatitis B Treatment in Ethiopia
T2 - 18-Month Follow-Up
AU - Tappata, Manaswita
AU - Farah, Marina
AU - Anugwom, Chimaobi
AU - Bisrat, Eden
AU - Seid, Amir S.
AU - Debes, Jose D.
N1 - Publisher Copyright:
© 2023 American Society of Tropical Medicine and Hygiene. All rights reserved.
PY - 2023/11
Y1 - 2023/11
N2 - There is a lack of real-world data on hepatitis B (HBV) treatment in Africa. We conducted a single-center 18-month prospective cohort study in Ethiopia to understand clinical, laboratory, and demographic variables associated with HBV treatment. One hundred fifty HBV-positive patients were included: 51 on treatment, 99 with no treatment. Median age was similar between groups. Those on treatment were more likely to be male (86%), report higher coffee intake (90% versus 70%, P, 0.05), lower khat intake (0% versus 9%, P 5 0.08), lower alcohol consumption (0% versus 5%, P 5 0.1), and had attained higher levels of education (56% versus 42%, P 5 0.19). Individuals on treatment had higher median aspartate aminotransferase (AST), alanine aminotransferase (ALT), HBV DNA, and median Aminotransferase-to-Platelet Ratio Index and Fibrosis-4 scores. At 6 and 12 months, those on treatment showed a decrease in median AST, ALT, and fibrosis scores and had less hepatocellular carcinoma development at 6 months (2% versus 4%). Our study highlights potential demographic disparities in HBV treatment as well as benefits in a real-life setting in Africa.
AB - There is a lack of real-world data on hepatitis B (HBV) treatment in Africa. We conducted a single-center 18-month prospective cohort study in Ethiopia to understand clinical, laboratory, and demographic variables associated with HBV treatment. One hundred fifty HBV-positive patients were included: 51 on treatment, 99 with no treatment. Median age was similar between groups. Those on treatment were more likely to be male (86%), report higher coffee intake (90% versus 70%, P, 0.05), lower khat intake (0% versus 9%, P 5 0.08), lower alcohol consumption (0% versus 5%, P 5 0.1), and had attained higher levels of education (56% versus 42%, P 5 0.19). Individuals on treatment had higher median aspartate aminotransferase (AST), alanine aminotransferase (ALT), HBV DNA, and median Aminotransferase-to-Platelet Ratio Index and Fibrosis-4 scores. At 6 and 12 months, those on treatment showed a decrease in median AST, ALT, and fibrosis scores and had less hepatocellular carcinoma development at 6 months (2% versus 4%). Our study highlights potential demographic disparities in HBV treatment as well as benefits in a real-life setting in Africa.
UR - http://www.scopus.com/inward/record.url?scp=85176496177&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85176496177&partnerID=8YFLogxK
U2 - 10.4269/ajtmh.23-0236
DO - 10.4269/ajtmh.23-0236
M3 - Article
C2 - 37696510
AN - SCOPUS:85176496177
SN - 0002-9637
VL - 109
SP - 1161
EP - 1165
JO - American Journal of Tropical Medicine and Hygiene
JF - American Journal of Tropical Medicine and Hygiene
IS - 5
ER -